Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
- PMID: 18458229
- DOI: 10.1212/01.wnl.0000311391.00944.c4
Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Abstract
Objective: To perform an evidence-based review of the safety and efficacy of botulinum neurotoxin (BoNT) in the treatment of adult and childhood spasticity.
Methods: A literature search was performed including MEDLINE and Current Contents for therapeutic articles relevant to BoNT and spasticity. Authors reviewed, abstracted, and classified articles based on American Academy of Neurology criteria (Class I-IV).
Results: The highest quality literature available for the respective indications was as follows: adult spasticity (14 Class I studies); spastic equinus and adductor spasticity in pediatric cerebral palsy (six Class I studies).
Recommendations: Botulinum neurotoxin should be offered as a treatment option for the treatment of spasticity in adults and children (Level A).
Comment in
-
Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review).Neurology. 2009 Sep 1;73(9):736; author reply 737-8. doi: 10.1212/WNL.0b013e3181af0b6e. Neurology. 2009. PMID: 19720984 No abstract available.
Similar articles
-
Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.Neurology. 2008 May 6;70(19):1707-14. doi: 10.1212/01.wnl.0000311390.87642.d8. Neurology. 2008. PMID: 18458231
-
Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.Neurology. 2008 May 6;70(19):1699-706. doi: 10.1212/01.wnl.0000311389.26145.95. Neurology. 2008. PMID: 18458230 Free PMC article.
-
Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome.Toxicon. 2013 Jun 1;67:115-28. doi: 10.1016/j.toxicon.2012.11.025. Epub 2012 Dec 5. Toxicon. 2013. PMID: 23220492 Review.
-
Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review).Neurology. 2009 Sep 1;73(9):736-7; author reply 737-8. Neurology. 2009. PMID: 19728407 No abstract available.
-
Botulinum Toxin Treatment of Spasticity in Adults and Children.Semin Neurol. 2016 Feb;36(1):64-72. doi: 10.1055/s-0036-1571847. Epub 2016 Feb 11. Semin Neurol. 2016. PMID: 26866498 Review.
Cited by
-
Efficacy of selective neurotomy for focal lower limb spasticity: a systematic review.J Rehabil Med. 2024 Sep 10;56:jrm39947. doi: 10.2340/jrm.v56.39947. J Rehabil Med. 2024. PMID: 39254381 Free PMC article.
-
Gait Reconstruction Strategy Using Botulinum Toxin Therapy Combined with Rehabilitation.Toxins (Basel). 2024 Jul 19;16(7):323. doi: 10.3390/toxins16070323. Toxins (Basel). 2024. PMID: 39057963 Free PMC article. Review.
-
The Role of Botulinum Toxin Type-A in Spasticity: Research Trends from a Bibliometric Analysis.Toxins (Basel). 2024 Apr 9;16(4):184. doi: 10.3390/toxins16040184. Toxins (Basel). 2024. PMID: 38668609 Free PMC article. Review.
-
Selecting Goals and Target Muscles for Botulinum Toxin A Injection Using the Goal Oriented Facilitated Approach to Spasticity Treatment (GO-FAST) Tool.Toxins (Basel). 2023 Nov 29;15(12):676. doi: 10.3390/toxins15120676. Toxins (Basel). 2023. PMID: 38133180 Free PMC article.
-
Botulinum Neurotoxins: From Toxin to Medicine.Toxins (Basel). 2023 Oct 20;15(10):621. doi: 10.3390/toxins15100621. Toxins (Basel). 2023. PMID: 37888652 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
